Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

DNA vaccines targeting heavy chain C-terminal fragments of Clostridium botulinum neurotoxin serotypes A, B, and E induce potent humoral and cellular immunity and provide protection from lethal toxin challenge.

Scott VL, Villarreal DO, Hutnick NA, Walters JN, Ragwan E, Bdeir K, Yan J, Sardesai NY, Finnefrock AC, Casimiro DR, Weiner DB.

Hum Vaccin Immunother. 2015;11(8):1961-71. doi: 10.1080/21645515.2015.1066051.

2.

An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman Primates.

Wise MC, Hutnick NA, Pollara J, Myles DJ, Williams C, Yan J, LaBranche CC, Khan AS, Sardesai NY, Montefiori D, Barnett SW, Zolla-Pazner S, Ferrari G, Weiner DB.

J Virol. 2015 Sep;89(18):9154-66. doi: 10.1128/JVI.00652-15. Epub 2015 Jun 17.

3.

HIV-1 Env DNA vaccine plus protein boost delivered by EP expands B- and T-cell responses and neutralizing phenotype in vivo.

Muthumani K, Wise MC, Broderick KE, Hutnick N, Goodman J, Flingai S, Yan J, Bian CB, Mendoza J, Tingey C, Wilson C, Wojtak K, Sardesai NY, Weiner DB.

PLoS One. 2013 Dec 31;8(12):e84234. doi: 10.1371/journal.pone.0084234. eCollection 2013.

4.

Co-Administration of Molecular Adjuvants Expressing NF-Kappa B Subunit p65/RelA or Type-1 Transactivator T-bet Enhance Antigen Specific DNA Vaccine-Induced Immunity.

Shedlock DJ, Tingey C, Mahadevan L, Hutnick N, Reuschel EL, Kudchodkar S, Flingai S, Yan J, Kim JJ, Ugen KE, Weiner DB, Muthumani K.

Vaccines (Basel). 2014 Mar 25;2(2):196-215. doi: 10.3390/vaccines2020196.

5.

Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria.

Sonnenberg GF, Monticelli LA, Alenghat T, Fung TC, Hutnick NA, Kunisawa J, Shibata N, Grunberg S, Sinha R, Zahm AM, Tardif MR, Sathaliyawala T, Kubota M, Farber DL, Collman RG, Shaked A, Fouser LA, Weiner DB, Tessier PA, Friedman JR, Kiyono H, Bushman FD, Chang KM, Artis D.

Science. 2012 Jun 8;336(6086):1321-5. doi: 10.1126/science.1222551. Epub 2012 Jun 6.

6.

Intradermal DNA vaccination enhanced by low-current electroporation improves antigen expression and induces robust cellular and humoral immune responses.

Hutnick NA, Myles DJ, Ferraro B, Lucke C, Lin F, Yan J, Broderick KE, Khan AS, Sardesai NY, Weiner DB.

Hum Gene Ther. 2012 Sep;23(9):943-50. doi: 10.1089/hum.2012.055. Epub 2012 Aug 2.

7.

Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo.

Hutnick NA, Myles DJ, Bian CB, Muthumani K, Weiner DB.

Curr Opin Virol. 2011 Oct;1(4):233-40. doi: 10.1016/j.coviro.2011.08.003. Epub 2011 Sep 7. Review.

8.

An optimized SIV DNA vaccine can serve as a boost for Ad5 and provide partial protection from a high-dose SIVmac251 challenge.

Hutnick NA, Myles DJ, Hirao L, Scott VL, Ferraro B, Khan AS, Lewis MG, Miller CJ, Bett AJ, Casimiro D, Sardesai NY, Kim JJ, Shiver J, Weiner DB.

Vaccine. 2012 May 2;30(21):3202-8. doi: 10.1016/j.vaccine.2012.02.069. Epub 2012 Mar 8.

PMID:
22406458
9.

Clinical applications of DNA vaccines: current progress.

Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE, Weiner DB.

Clin Infect Dis. 2011 Aug 1;53(3):296-302. doi: 10.1093/cid/cir334. Review.

10.

Vaccination with Ad5 vectors expands Ad5-specific CD8 T cells without altering memory phenotype or functionality.

Hutnick NA, Carnathan DG, Dubey SA, Cox KS, Kierstead L, Makadonas G, Ratcliffe SJ, Lasaro MO, Robertson MN, Casimiro DR, Ertl HC, Betts MR.

PLoS One. 2010 Dec 22;5(12):e14385. doi: 10.1371/journal.pone.0014385.

11.

Perforin and IL-2 upregulation define qualitative differences among highly functional virus-specific human CD8 T cells.

Makedonas G, Hutnick N, Haney D, Amick AC, Gardner J, Cosma G, Hersperger AR, Dolfi D, Wherry EJ, Ferrari G, Betts MR.

PLoS Pathog. 2010 Mar 5;6(3):e1000798. doi: 10.1371/journal.ppat.1000798.

12.

Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive.

Hutnick NA, Carnathan D, Demers K, Makedonas G, Ertl HC, Betts MR.

Vaccine. 2010 Feb 23;28(8):1932-41. doi: 10.1016/j.vaccine.2009.10.091.

13.

Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells.

Hutnick NA, Carnathan DG, Dubey SA, Makedonas G, Cox KS, Kierstead L, Ratcliffe SJ, Robertson MN, Casimiro DR, Ertl HC, Betts MR.

Nat Med. 2009 Aug;15(8):876-8. doi: 10.1038/nm.1989. Epub 2009 Jul 20. Erratum in: Nat Med. 2009 Nov;15(11):1333. Makedonas, George [added].

14.

Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans.

O'Brien KL, Liu J, King SL, Sun YH, Schmitz JE, Lifton MA, Hutnick NA, Betts MR, Dubey SA, Goudsmit J, Shiver JW, Robertson MN, Casimiro DR, Barouch DH.

Nat Med. 2009 Aug;15(8):873-5. doi: 10.1038/nm.1991. Epub 2009 Jul 20.

15.

AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells.

Mingozzi F, Meulenberg JJ, Hui DJ, Basner-Tschakarjan E, Hasbrouck NC, Edmonson SA, Hutnick NA, Betts MR, Kastelein JJ, Stroes ES, High KA.

Blood. 2009 Sep 3;114(10):2077-86. doi: 10.1182/blood-2008-07-167510. Epub 2009 Jun 8.

16.

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, Sullivan P, Mahany JJ, Gallagher M, Kramer A, Green SJ, O'Dwyer PJ, Running KL, Huhn RD, Antonia SJ.

J Clin Oncol. 2007 Mar 1;25(7):876-83.

PMID:
17327609
17.

Exercise and lymphocyte activation following chemotherapy for breast cancer.

Hutnick NA, Williams NI, Kraemer WJ, Orsega-Smith E, Dixon RH, Bleznak AD, Mastro AM.

Med Sci Sports Exerc. 2005 Nov;37(11):1827-35.

PMID:
16286849

Supplemental Content

Loading ...
Support Center